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Abstract: Transposable elements (TEs) comprise nearly half of the human genome and play an
essential role in the maintenance of genomic stability, chromosomal architecture, and transcriptional
regulation. TEs are repetitive sequences consisting of RNA transposons, DNA transposons,
and endogenous retroviruses that can invade the human genome with a substantial contribution in
human evolution and genomic diversity. TEs are therefore firmly regulated from early embryonic
development and during the entire course of human life by epigenetic mechanisms, in particular
DNA methylation and histone modifications. The deregulation of TEs has been reported in some
developmental diseases, as well as for different types of human cancers. To date, the role of TEs,
the mechanisms underlying TE reactivation, and the interplay with DNA methylation in human
cancers remain largely unexplained. We reviewed the loss of epigenetic regulation and subsequent
genomic instability, chromosomal aberrations, transcriptional deregulation, oncogenic activation,
and aberrations of non-coding RNAs as the potential mechanisms underlying TE deregulation in
human cancers.
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1. Introduction
Over two-thirds of the human genome is composed of repetitive sequences [1]. Transposable
elements (TEs), which make up the majority of repetitive sequences (up to 50% of the human
genome), can jump within the genome and play an important role as an engine for the dynamics of
human evolution and the pathogenesis of human cancers [2]. TEs are classified according to their
transposition mechanisms into retrotransposons (Class I) and DNA transposons (Class II) [3,4]. Class I
retrotransposons are further sub-classified into long terminal repeats (LTRs) or endogenous retrovirus
(ERV) elements that make up 8% of the human genome, and non-LTRs, which include the two most
important TEs in cancers, long interspersed nuclear elements (LINEs) and short interspersed nuclear
elements (SINEs) [3,4]. LTRs are identical repeated DNA sequences originating from the integration of
ancient retroviruses into the human genome that have lost their ability as mobile elements. On the
other hand, non-LTRs with autonomous and nonautonomous retrotranspositions (LINEs and SINEs,
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respectively) retain their ability as active mobile elements in the human genome. LINE1 sequences
represent up to 17% of the human genome [3,4]. Although LINE1 is considered the most active mobile
element in a human, around 500,000 copies no longer have the ability to mediate retrotransposition due
to significant LINE1 truncations [5]. However, new full length LINE1 would be able to encode proteins
that are very efficient to “copy and paste” into a new genetic location and hamper the associated gene
expression and/or drive oncogenic process through the transcription of chimeric proteins [5].
Active TEs are considered highly mutagenic and are associated with the multiple steps of cancer
development and progression [2,6]. TEs have been demonstrated to play an active role in regulating the
human genome by governing endogenous gene expression, as well as generating novel genetic loci [7].
However, TE activity might have different impacts on the human genome ranging from positive to
negative consequences, including the maintenance of centromere and telomere integrity, recombinant
genome remodeling, and deleterious gene expression [3,7]. In addition, the accumulation of TEs
throughout human evolution has been adapted into novel functions through several mechanisms,
known as domestication. The co-opting of TEs can be delivered through several ways such as
the formation of a new gene entity, integration into an existing gene generating a chimeric protein,
and insertion into a regulatory region upstream of a gene to further regulate gene expression by forming
alternative promoters or altering transcriptional binding sites [8,9]. In addition, the integration of TEs
into introns might interfere with transcription, alternative-splicing, polyadenylation, and messenger
RNA stability [3,10,11].
A growing body of evidence has documented the essential role of TEs in human carcinogenesis.
The insertion of TEs into genes that are responsible for DNA repair including BRCA2 [12], APC [13],
and RB1 [14] can cause the disruption of gene expression and further affect genome instability [15].
Methylation loss of a specific LINE1 promoter is able to activate an alternative transcript that encodes a
truncated and constitutively active MET protein in bladder cancer [16]. De novo insertions of LTR and
LINE sequences cause an alternative transcription of a new isoform in an ALK (anaplastic lymphoma
kinase) gene [17]. The new ALK isoform is specifically expressed in around 11% of melanomas that
further show a specific response to the ALK inhibitor [17]. A comprehensive approach in diffuse large
B-cell lymphomas (DLBCLs) has detected multiple LTR transcripts in several genes, including fatty-acid
binding protein 7 (FABP7); that are known to promote lymphomagenesis [18]. The reactivation of
ancient LTR has also been associated with the novel oncogenic transcription of ERBB4 in ALK-negative
anaplastic large cell lymphoma (ALCL) [19]. Two aberrant ERBB4 transcripts are found in almost
a quarter of ALK-negative ALCL patients [19]. Despite their important roles in genome regulation,
the detailed mechanisms of TE reactivation in tumor development remain largely unexplained.
TEs are tightly regulated from early embryonic development and during the entire human
life [20]. Epigenetic mechanisms, particularly DNA methylation and histone modifications, are the
best known mechanisms underlying the repression and regulation of TEs [3,21]. In relation to human
cancers, epigenetic alterations have also been continuously reported to play a significant role in the
initiation of tumor development [22]. A growing number of studies have delineated that epigenetic
mechanisms may also control TE reactivation with subsequent effects on carcinogenesis [2,21].
The hypermethylation of tumor suppressor genes accompanied by global hypomethylation occurs
consecutively in human cancers [22,23]. Moreover, the global loss of methylation subsequently
results in the reactivation of TEs [3,21,24]. In cancers, hypomethylation and TE activation are
dynamic processes during tumor evolution and progression [25–27]. The reactivation of TEs could
initiate oncogene activation [16,25], chromosomal breakages [28], and genomic instability [27] that
further contribute to tumor initiation and progression [16,27]. To obtain a better understanding of
this emerging area of research, we reviewed the current evidence on the deregulation of TEs by
epigenetic mechanisms, especially DNA methylation and non-coding RNAs, and their potential
contribution to the development of human cancers through genomic instability, chromosomal
aberrations, and oncogenic activation.
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2. Widespread Epigenetic Deregulation of Repetitive Elements in Cancer
TEs have been suggested to play an essential role in maintaining genome integrity [29]
and therefore, dysregulated TE activity may result in genomic instability and subsequent
carcinogenesis [5,30]. TEs and host regulatory factors cooperate in controlling TE activity through
overlapping multiple epigenetic mechanisms [31]. TEs are able to independently recruit silencing
signals to form robust building blocks of inactivation not only at the level of a single gene,
but also across large chromosomal regions [3,31]. In addition, self-control mechanisms by TEs
will initiate the repression of retrotransposition adverse effects while maintaining their ability to
replicate. The interdependency of host regulatory controls is mediated through the transcription
of truncated suppressor clones, the presence of splice sites and hidden polyadenylation signals,
and transposon-mediated autoregulation (as reviewed in [32]). Several other host regulatory defense
mechanisms are also involved in restricting TE activity. However, the primary regulators controlling
TE transcription are epigenetic mechanisms, mainly DNA methylation and histone modifications;
that effectively suppress TEs while maintaining their presence in the human genome [3,31]. In the
context of cancer, the loss of DNA methylation causing the reactivation of LINE1 has been reported
in colorectal cancer [26], hepatocellular carcinoma [33], and breast cancer [34]. Figure 1 describes the
effects of the loss of methylation on TE reactivation in a cancer cell.
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Figure 1. Global loss of DNA methylation in cancer cells leads to TE reactivation. A common epigenetic
feature in neoplastic cells is global demethylation, including within repeated sequences. Subsequently,
TE reactivation can cause increasing somatic retrotransposition, non-coding RNA, and transcriptional
deregulation. Red arrows show direct impacts of TE reactivation and black arrows show effects
of retrotransposition.
The hypomethylation of LINE1 is reported in both solid tumors and leukemia, and is frequently
correlated with unfavorable clinical outcomes [26,35]. In addition, the hypomethylation of LINE1 and
Alu in circulating blood has potential value for cancer diagnoses [36]. Exposure to DNA demethylation
agents including azacytidine and decitabine leads to LINE1 demethylation, as well as subsequent
activation, and is followed by oncogene activation [16]. The human endogenous retroviruses (HERVs)
are also related to carcinogenesis. Increased levels of HERV RNA and reverse transcriptase enzymes
have been rep rted i lymphomas and breast canc s [37]. In addition, HERV-like-viruses have also
been associa d with melano s, especi ly those with metastases [37]. Ovarian, colon, a d testicular
cancers express higher levels of envelope genes of HERV [37].
Heterochromatin formation has also been associated with the regulation of TE silencing in
cooperation with DNA methylation and small RNAs [31]. Histone tail modifications affect the binding
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of protein and transcription factors. TE-associated nucleosomes are commonly methylated at the
histone 3 lysine 9 (H3K9) representing signals for transcriptional silencing and inactive chromatin [38].
Mutations of H3K9 methyltransferases including SUV39 cause TE upregulation [39,40]. In addition, the
deregulation of DNA methyltransferase during embryonic development leads to increased TE activity
and is associated with some developmental disorders [31,41]. Specific patterns of DNA sequences
and non-coding RNAs are implicated in the direct de novo and maintenance DNA methylation of
specific genomic loci, including repetitive sequences [22,31]. Chromatin structure-modifying proteins
implicated in chromatin remodeling and condensation are also involved in TE silencing [31,42].
Several TEs, particularly SINEs, contain binding sites for CTCF that function as an insulator and
consecutively regulate chromatin condensation [43,44]. A recent study by Pugacheva et al. showed
the specific binding of CTCF and BORIS to DNA repeats in which BORIS preferentially bound to SVA
repeats (SINEs, VNTRs, Alus), suggesting a potential role of BORIS in the regulation of active TEs in
cancer cells [45]. DDM1, LSH1, SETDB1, and KDM1A are among numerous chromatin remodeling
proteins that regulate and maintain TE inactivation [46]. Especially in mammals, DNA methylation,
along with chromatic remodeling factors and non-coding RNAs, are responsible for keeping TEs in
a dormant state [42]. However, recent evidence suggests that different mechanisms are involved in
regulating TEs during embryogenesis, mainly through using histone modifying enzymes such as
KDM1A and SETDB1 [21,46]. Upon epigenetic silencing, TEs are kept inactive to allow their embedded
regulatory regions to be exapted. Mutations and the deregulation of chromatin remodeling genes are
closely related with human cancers of different etiologies [47,48]. However, their direct effects on the
reactivation of repetitive elements in cancers to initiate genomic instability and oncogenic activation
need to be clarified [49,50].
3. Transcriptional Deregulation
TEs are able to modulate gene transcription by insertion into transcriptional regulatory regions [3].
TE insertions can induce functional defects of regulatory regions, including promoters, enhancers, or
silencers [3]. TE integrations are able to create new exons that interfere with the biological functions
of the host gene product. The insertion of TE within exons might alter the open reading frame
(ORF) and initiate missense or nonsense mutations that can consecutively destroy transcription factor
binding sites [3]. By contrast, insertion into gene regulatory and coding regions can introduce new
splice sites [51], perturb the canonical splice sites [52], or create new polyadenylation signals [10].
Insertions of TE into introns are also able to create alternatively spliced exons that are biologically
functional [52,53]. For instance, Alu sequences are commonly found to create new exons in mature
transcripts upon insertion [51,53]. Sorek et al. reported that more than 80% of Alu insertions in the
exons caused either a frame-shift or premature stop codon [54]. In addition, TE insertions in 3′UTRs
and introns affect mRNA stability, localization, and translation [11], causing a reduction of gene
expression. Transcription factors that are commonly involved in carcinogenesis, including FOXA1 [55],
SP1 [56], GATA [57], P53 [58], and retinoic acid receptors [59], have binding sites in Alu elements [58].
In addition, p53 binding sites have been found to interact with several LTR- and non LTR elements.
It is predicted that around 400,000 p53 binding sites of the human genome are associated with the Alu
element [58]. The deregulation of transcription factor p53 affects the expression of many other genes
and is suggested to be involved in more than half of human cancers [60]. Mutations of the TP53 gene
cause an elevated activity of RNA polymerase III [61]. Levels of Alu RNA expression are increased in
many cancers, including hepatocellular carcinoma and lung cancer [61]. It seems that the p53 binding
to Alu sequences accompanied by transcriptional repression can trigger the deregulation of multiple
genes [58]. It has recently been shown that p53 is able to restrain retrotransposon activity through
direct interactions with the PIWI-interacting RNA pathway [62].
TE insertions within the genome are considered to be non-random events, as the insertions might
affect transcriptional regulation [3,63]. It has been documented that TE integrations caused significant
alterations in several cis-regulatory elements of gene expression [63]. A comprehensive analysis
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using ChIP-seq has revealed that almost 20% of transcription factor binding sites are embedded
within TEs [63]. TEs are able to divide the genome into transcriptionally active or inactive regions
by influencing the extent of heterochromatin formation [64]. The effects of retrotransposition on
gene transcription in human cancer are summarized in Figure 2. Cancer-associated genes that are
transcriptionally modulated by TE insertions are recapitulated in Table 1.
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Figure 2. Effects of retrotransposition on transcriptional deregulation. Insertion of TEs into (A) coding
region can disturb or eliminate gene functions; (B) upstream of the gene loci can introduce a novel
alternative promoter leading to the variation of protein products; (C) promoter region can disrupt
cis-regulatory elements, as well as transcriptional start sites; (D) introns can introduce epigenetic
remodeling events including DNA methylation and chromatin condensation, leading to gene silencing.
At the post-transcription l step, the introduction of TEs (E) in the introns can cause alternative splicing
that causes various protein products and functions; (F) at the 3′UTR can int oduce poly-adenylation
sites leading to unstable mRNAs; and (G) at the 3′-UTR can create binding si es for miRNAs
and other ncRNAs. Therefore, retrotransposition affects the efficiency of gene transcription and
post-transcriptional regulation, and is associated with the deregulation of gene expression during
human carcinogenesis.
Table 1. TE-associated transcriptional deregulation in human cancers.
Locus or Genes TE(s) Mechanisms Associated Cancers References
ADARB1 Alu Alternative splicing Lung, brain cancer [65–67]
AKR1A1 Alu Alternative splicing Head and n ck cancer [65,68]
ALS2CR8 LINE1 silencing olorectal cancer [2]
ANKS1B_ Alu Dele on, silencing Colorectal cancer [2]
ANO9 LINE1 Alter ativ splicing olorectal cancer [2]
ADH1C LTR Primary ro oter Cancers [65,69]
ALK LINE1, LTR lternative promoter Melanoma, cancers [17]
APOA LINE1 Enhancer Cancers [65,70]
APOC LTR Alternative promoter Gastric cancer [65]
ARNT Alu Alternative splicing Lung cancer, metastasis of different cancers [65]
ARHGEF12 LINE1 Alternative splicing Ovarian cancer [2]
ASMT LINE1 Alternative splicing Glioma [65]
B3GALNT2 Alu Alternative splicing Breast cancer [65]
B3GALT5 Alu Alternative promoter Breast cancer [65]
BAAT LTR Primary promoter Lung cancer [65]
BAHCC1 Alu Alternative splicing Colorectal cancer [65]
BBS7 LINE1 Primary promoter Prostate cancer [2]
BLVRA Alu Alternative splicing Breast cancer [65]
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Table 1. Cont.
Locus or Genes TE(s) Mechanisms Associated Cancers References
C19MC miRNA Alu POL III promoter Hepatocellular, human cancers [35,65,71]
CA1 LTR Primary promoter Colorectal cancer [8,72]
CASPR4 LTR Alternative promoter Breast cancer, nasopharyngeal cancer [65]
CD8A LTR Enhancer Colorectal, pancreatic cancer [65]
CDH12, CDH20 LINE1 Alternative splicing Colorectal cancer [2]
CHRM3 LINE1 Alternative promoter Endometrial cancer [65]
CHRNA1 Alu Alternative splicing Testicular cancer [65]
CLDN14 LTR Alternative promoter Hepatocellular carcinoma [65]
COL11A1, COL9A1 LINE1 Alternative splicing Colorectal, prostate cancer [2]
COX7B2 LINE1 Alternative splicing Prostate cancer [2]
CTNNA2 LINE1 Alternative splicing Colorectal cancer [2]
CWF19L1 Alu Alternative splicing Breast cancer [65]
CYB561D1 Alu Alternative splicing Lung cancer [65]
CYP19A1 LTR Alternative promoter Breast cancer [65]
CUL3 LTR Alternative splicing Lung cancer [73]
DAPK1 ERV1 Alternative splicing Multiple myeloma [2]
DBC1 LINE1 Deletion, Alternative promoter Colorectal cancer [2]
DHRS2 LTR Alternative promoter Breast cancer [65]
DNMT1 Alu Alternative splicing Different cancers [65,74]
DSCR4, DSCR8 LTR Primary promoter Colorectal cancer [65]
EPHA6 LINE1 Alternative transcript Colorectal cancer [2]
ERBB4 LTR Alternative promoter Lymphoma, colorectal cancer [2,19]
EBR LTR Alternative promoter Bladder cancer [65]
FABP7 LTR Alternative promoter Lymphoma [18]
FLT4/VEGFR3 LTR Alternative splicing Different cancers [65]
FMO1 LINE1 Silencer Lung cancer [65]
FOXP2 LINE1 Alternative promoter Ovarian cancer [2]
FUT5 LINE1, Alu Alternative splicing Colorectal cancer [65]
GABRG3 LINE1 Alternative splicing Colorectal cancer [2]
GBP5 LTR Primary promoter Breast cancer [65]
HHLA2, HHLA3 LTR Polyadenylation signal Bladder cancer [65]
HINFP/ZNF743 Alu Alternative splicing Lung cancer [65]
HYAL-4 LINE1, Alu Primary promoter Cancers [8,75]
IFNγ Alu Binding sites Cancers [65]
KCNH6 Alu, LTR Alternative splicing Endometrial cancer [76,77]
KDR LINE1 Alternative promoter Colorectal cancer [2]
MCTP2 LINE1 Deletion, Alternative promoter Colorectal cancer [2]
MET LINE1 Alternative splicing Bladder cancer [16]
MKKS LTR Alternative promoter Colorectal cancer [65]
MSLN LTR Primary promoter Pancreatic cancer [65]
NAIP Alu Alternative promoter Cancer [78]
NFKBID Alu Alternative splicing Colorectal cancer [65]
NOS3, NOSIP LR Alternative promoter Different cancers [65]
NPAS3 LINE1 Alternative promoter Colorectal cancer [2]
NRXN3 LINE1 Alternative splicing Colorectal cancer [2]
RB1 LTR Alternative promoter Hepatocellular carcinoma, retinoblastoma [14,79]
ROBO2 LINE1 Alternative splicing Colorectal cancer [2]
SLCC44A5, SLC35F1 LINE1 Alternative promoter, slencing Colorectal cancer [2]
SRY LTR Alternative transcript Wilm’s tumor [80,81]
STXBP5L LINE1 Alternative promoter Colorectal cancer [2]
TMED7 Alu Alternative promoter Colorectal cancer [2]
TMEM16J, TMEM56 Alu Alternative splicing, silencing Colorectal cancer [2]
TMPRSS3 Alu, LTR Alternative transcript Breast, ovarian cancer [8,82,83]
TP53 Alu Binding sites Cancers, Pancreatic cancer [58]
P63 LTR Primary promoter Breast cancer [65]
PDZK1 Alu Alternative splicing Lung cancer [65]
PODXL Alu Alternative splicing Pancreatic cancer [65]
PTN LTR Alternative promoter Different cancers [65]
ZNF451 LTR Alternative splicing Hematological cancer [9,84]
ZNF177, ZNF257,
ZNF418 LINE1, Alu Alternative splicing Different cancers [65]
TEs also interact with non-coding RNAs, including microRNAs and lncRNAs, to modulate
transcription, as discussed below. TEs use other mechanisms to influence gene expression, including
the spreading of repressive chromatin signals to adjacent regions in order to silence the nearby
genes [85]. In addition, TEs disrupt gene expression through chromosomal integration that can result
in shorter 3′UTR and polyadenylation signal disruption [86]. The insertion of an Alu element into the
NF-1 gene has been shown to cause deletion and reading frame-shift, leading to the development of
neurofibromatosis [87].
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4. Genomic Instability and Chromosomal Rearrangements
The vast majority of TE insertions target particular genomic loci that are specifically recognized
by endonuclease domains causing alterations of adjacent gene expression and significant genomic
deletions [88]. Under certain conditions, random TE integrations can lead to insertional mutagenesis [2].
Genomic variations affected by TE mobility include the loss of heterozygocity insertion, deletion,
duplication, translocation, and inversion [2,15,89]. Gene mutations caused by retrotransposon
insertions are found in around 0.3% of total mutations [2]. Several mechanisms leading to TE-mediated
genomic instability in cancer have been reported. First, the insertion of inverted TEs in the human
genome can induce DNA damage [90]. Because TEs are naturally very mobile, there is a high chance for
insertion in an inverse orientation. Several adjacent Alu and short sequence repeats that are inversely
inserted during DNA replication tend to form a secondary hairpin structure that is susceptible to
double-strand breaks (DSBs) [90,91]. However, the arrangement of inverted Alu elements in the human
genome is relatively rare. In some parts, there is a tendency for the direct orientation of newly adjacent
Alu insertion to prevent secondary hairpin formation [92]. Despite the unusual nature of closely
inverted Alu insertion, the fact that unregulated Alu insertions frequently occur in cancer has increased
the probability of de novo inverted insertions [93].
The second mechanism of TE-mediated genomic instability is the induction of unstable
microsatellite seeding after TE insertions [15]. Mutations in the poly-A tail are able to initiate the
seeding of large tracts of unstable microsatellite repetitive sequences [15]. If located in fragile sites
of the human genomes, the unstable microsatellites can induce carcinogenesis [15]. In addition,
the expansion of intronic microsatellite sequences is able to disrupt gene transcription, as shown in
Friedrich’s ataxia [94]. Microsatellite instability is an important feature of several colorectal, stomach,
endometrium, ovary, urinary tract, skin, and brain cancers [95]. In addition, the incorporation of TEs
into introns can produce unstable long repeats in the microsatellites, causing these regions to become
highly unstable and vulnerable to DNA damage [15,95].
TE-mediated genomic instability is also associated with alterations in the overall transcription
in cancer. As previously mentioned, TE mobility can induce aberrant and recombinant gene
transcription [58]. The interplay between the replication fork and transcription factors has significantly
increased the chances of DNA damage [95]. The TE-mediated introduction of novel alternative
promoters is capable of elevating the overall levels of stress-associated gene expression that may further
increase DNA damage rates [89,96]. The majority of cancers represent epigenetic reprogramming with
global widespread hypomethylation that can increase the transcriptional activity and mobility of these
TEs, thus increasing the probability of transcriptional stress-associated DNA damage. Transcriptional
stress and DNA damage are the major contributors of genomic instability in cancers [97].
The induction of genomic instability by TE insertion will induce host DNA repair signaling.
The recruitment of the DNA repair machinery to the TE insertion loci is accompanied by cell cycle
arrest affecting the relative efficiency of TE mobility. However, TE insertion also targets genes that are
involved in the DNA repair pathway. The breast cancer susceptibility gene BRCA2 has been affected
by multiple TE insertions in cancers [12,98]. In addition, the APC gene is also disrupted by multiple TE
insertions (Alu and LINE1) and is suggested to play a role in colorectal carcinogenesis [13,99]. Voineagu
et al. have suggested that inverted repeat sequences might emerge as fragile sites inducing genomic
instability [90]. LINE1 endonucleases are eminent sources of DSBs that subsequently affect genomic
instability [100]. In addition, LINE1 transposition causes DNA breakage and, even after DNA repair,
this event still produces the deletion of a few base pairs [101,102]. In addition, genotoxic stress by a low
dose of radiation results in LINE1 activation and is associated with the initiation of carcinogenesis [103].
TE-associated genes that lead to deletions or variations of a few base pairs (genomic instability) in
human cancer are summarized in Table 2.
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Table 2. TE insertion-associated loss or gain of a few base pairs and mutagenesis in human cancers.
Locus or Genes TE(s) Associated Cancers References
APC Alu Colon cancer [13,99]
BRCA1 Alu Breast, ovarian cancer [12,98,104]
BRCA2 Alu Breast, ovarian cancer [12,98,104]
CASPR4 LTR Brain cancers [8,105]
CHEK2 Alu Breast, ovarian, prostate cancer [104,106]
CLDN14 LTR Melanoma [8,107]
CYP19 LTR Breast cancer [8,108]
ENTPD1 LTR Melanoma [8,109]
FUT5 LINE1, Alu Gastric cancer [8,110]
HSD17B1 LTR Breast, endometrial cancers [111]
HRAS LTR T-cell leukemia [112]
MLH1 Alu Colorectal cancer [2,113]
MLVI2 Alu Leukemia [114]
MKKS LINE2, LTR Embryonic cancers [8,115]
MLH2 Alu Colorectal cancer [113]
MYC LINE1 Breast cancer [116]
NF1 Alu Neurofibromatosis type I [87]
MSLN LTR Human cancers [8,117]
RB1 Alu, LTR Retinoblastoma, hepatocellular cancer [14,79]
TCF3-PBX1 LTR ALL [118]
TRPC6 LTR Breast, prostate, gastric cancers, glioma [76,119]
TE insertions have also been associated with chromosomal rearrangement. Alu sequences are
frequently found in several breakage points of chromosomal translocations and are closely associated
with cancer [120]. TE insertion-mediated deletions and chromosomal rearrangement were reported
upon pathogenic LINE1 and Alu insertions [121,122]. TE-mediated insertions can cause deletions,
ranging from a few to several thousand nucleotides in size [122]. Novel LINE1 insertions often target
endogenous elements, suggesting a preference for specific incorporation sites [5,121]. Chromosomal
rearrangements frequently occur in rather prone regions during TE insertions. Subsequently, host DNA
repair systems will try to eliminate nascent TE insertions to limit the impacts on genome instability
and chromosomal rearrangement [101,123].
TE-associated chromosomal rearrangements are also mediated by segmental duplications that
are relatively common in the human genome [124]. Segmental duplications have been established
as significant factors in genome evolution, as well as in the development of human cancer.
A comprehensive analysis of the human genome has revealed segmental duplications with an increased
density of Alu repeats within or near the duplication intersections [124]. In humans, it is believed that an
outburst of Alu repeats can initiate segmental duplications [124,125]. However, the exact mechanisms
by which Alu and other TE species induce segmental duplications remain unclear. Homologous
repair is able to generate duplications by arranging replicons tandemly. However, the mechanism
underlying large duplication events with a distance of more than 1 Mb remains elusive. The relatively
frequent Alu element insertions at the junction of the segmental duplication, accompanied by the
involvement of evolutionarily young and identical elements, suggest that homology sequences guide
these events [124,125]. TE-associated genes that are affected by chromosomal aberrations in human
cancers are listed in Table 3.
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Table 3. TE-mediated chromosomal structure defects in human cancers.
Locus of Genes TE(s) Chromosomal Defects Associated Cancer References
BCR-ABL Alu Chromosomal translocation CML [126]
BRCA1 Alu Chromosomal deletion,duplication, insertion Breast, ovarian cancer [127]
BRCA2 Alu Chromosomal deletion,duplication, insertion Breast, ovarian cancer [12,128]
CAD Alu Chromosomal deletion Hepatocellular carcinoma [122]
CDH1 Alu Chromosomal deletion Diffuse gastric cancer [129]
EWSR1-ETV Alu, LINE1 Chromosomal translocation Ewing sarcoma [28]
MAD1L1 LTR Chromosomal instability Breast cancer [8,130]
MLL1 Alu Chromosomal duplication AML [131]
MYB Alu Chromosomal duplication T-ALL [132]
VHL Alu Chromosomal deletion von Hippel Lindau disease [133]
WT1 LINE1 Chromosomal translocation Sarcoma [28]
5. Inactivation of Tumor Suppressor Genes and Activation of Oncogenes
Random integrations of TEs into specific sites of the human genome increase the chance
for insertional mutagenesis followed by the activation of signaling pathways leading to
carcinogenesis [2,15]. LINE1, Alu, and SVA are among the most common TEs that frequently induce
insertional mutagenesis [2]. The activation of oncogenic drivers is also mediated by the deleterious
insertion of tumor suppressor genes and the disruption of regulatory sequences. The deregulation
of gene expression, splicing-induced truncated proteins, and destabilized mRNAs all contribute to
oncogenic activation [3,134]. In addition, genomic instability, including chromosomal breakages and
DNA recombination that can be induced by mobile TE insertions, reinforces mutation rates and
carcinogenesis [13,89,127].
Non-allelic homologous recombination causing deletions or duplications in the presence of
Alu is abundantly found in tumors with TP53 mutations [58]. The close proximity of several
Alu insertions tends to impose an inverted orientation, leading to the loss of p53 functions [58].
Alu sequences are also involved in mismatch repair (MMR) by disrupting MLH1 and MLH2
genes [92]. In addition, rearrangements due to Alu insertion and the presence of Alu in the
MLH1 and MLH2 proteins are associated with hereditary non-polyposis colorectal cancer [92].
Recombination events due to the high density of Alu elements within the BRCA1 gene are associated
with the important deregulation of genomic integrity in breast cancer [12,98]. Alu repeats have
also contributed significantly to chromosomal translocations, including BCR/ABL rearrangement
in chronic myelogeneous leukemia [126]. The recombination of Alu has also caused myoblastosis
(MYB) duplication to T-cell acute lymphoblastic leukemia [132]. Chromosomal rearrangements in
mixed-lineage leukemia (MLL) have also been reported due to Alu recombination [135]. Especially
in partial duplication events, TEs are usually inserted near the translocation breakpoints. MYB and
MLL duplications have also been found in healthy controls, whereas leukemogenesis is induced by
TE insertions during blood cell differentiation [136]. Additionally, Alu rearrangements have been
reported in the tumor suppressor gene von Hipple-Lindau (VHL) [133]. Compared to oncogenes,
tumor suppressor genes contain more Alu sequences [93].
6. Transposable Elements and Non-Coding RNAs
The interconnection between TEs and non-coding RNAs (ncRNAs) has been recently delineated,
especially in the biogenesis of small ncRNAs, including microRNAs that are associated with TEs.
MicroRNAs are small non-coding RNAs that regulate post-transcriptional gene expression and
modulate several important oncogenic pathways establishing a dynamic network of cell homeostasis
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(reviewed in [137,138]). A large number of microRNAs originate from loci flanked from two related TEs
in one genomic locus that is easily transcribed and processed into hairpin RNA structures following
common microRNA biogenesis [139,140]. Both bioinformatics and genome-wide screening have
identified a significant number of TE-based microRNA (up to 15% of total microRNAs) [140,141].
Several types of TEs are involved in microRNA biogenesis, especially DNA transposons, LINEs,
and SINEs [142]. The first example of TE-associated microRNA is hsa-mir-548 that derives from
inverted-repeat transposable elements [143]. The deregulation of TE is implicated in the disruption of
microRNA biogenesis. More importantly, TE-associated ncRNAs are involved in several important
regulatory networks and associated with some diseases. The involvement of lncRNAs in cancers and
their potential applications in clinical management of cancer have been comprehensively reviewed
in [144,145].
It has also been indicated that Alu insertions are able to create a targeting site for mRNA
decay by forming stable RNA/mRNA interactions through intra- or intermolecular base pairing
with 3′UTRs and complementary binding with RNA targets [146]. Hundreds of long non-coding
RNAs (lncRNAs, up tp 80%) contain endogenous insertions of TEs in human cells that serve as
regulatory signals for cell growth and proliferation [147]. Numerous long circular ncRNAs are
found in fibroblasts and act in a similar manner to “sponges” for miRNAs, in which intronic
Alu sequences that flank exon and the alternative formation of inverted Alu pairs are suggested
to greatly contribute to RNA circularization [148,149]. Therefore, the deregulation of TE might
interrupt ncRNA functions and is associated with the initiation of carcinogenesis. Alu and
LINE-embedded sequences also have regulatory roles for the transcription of lnc-RNAs and the
stability of mRNA products [150]. Since lncRNAs containing repeated sequences are also important
in the regulation of other epigenetic mechanisms, including genomic imprinting and chromatin
remodeling, the deregulation of this network is suggested to play a role in the development of human
cancer [143,150,151]. Carrieri et al. have delineated two functionally important regions in the antisense
lncRNAs, i.e., 5′-end and embedded SINEB2 and Alu elements that can interact with targeted mRNAs
to inhibit the translation. [152]. They also identified 31 antisense lncRNAs containing similar SINE/Alu
elements that might interact with 3′UTR mRNAs, suggesting an important role of TE-embedded
regions in the post-transcriptional regulation of gene expression [152].
Reciprocally, small non-coding RNAs including microRNAs have also been reported to regulate
genomic stability through direct or indirect transcriptional and post-transcriptional TE repression [150].
As cytoplasmic ncRNAs, microRNAs indirectly control DNA repair and genome stability [153]. siRNAs
mediate the trans enrolment of Ago complexes to subsequently regulate genome instability through
transcriptional repression and repetitive DNA element recombination [153]. In addition, the microRNA
biogenesis machinery has been inferred as an important regulator of heterochomatin formation
and transcriptional silencing. The AGO1 protein is reported to be involved in transcriptional gene
silencing through histone H3K9 methylation [154]. An initial report suggested that promoter DNA
methylation causing transcriptional silencing can be stimulated by a complementary siRNA to direct
DNA methylation into specific loci, including repetitive sequences [155]. Another mechanism of
ncRNA deregulation is the insertion into microRNA’s regulatory regions. Alu sequences occupy a large
portion of microRNA genes, as well as 3′UTR mRNA targets [156]. In general, tumors are able to avoid
miRNA-mediated regulation, causing a further enhancement of genomic instability and mutability
because of TE reactivation.
LncRNAs have been associated with myriads of important signaling pathways, most of which
require an interaction with proteins, as well as transcription factors. TE-associated lncRNAs are
reported to bind to some important transcription factors for cell proliferation, including p53, sp1,
and NF-Y [157]. In response to cellular stress, Alu RNAs are able to bind to RNA polymerase II to
regulate the expression of some responsive genes, as well as to promote evolution through exonization
and alternative splicing [158]. Analysis using mass spectrometry has revealed that Alu-derived piRNAs
are able to bind some nuclear proteins, suggesting their potential roles in DNA repair, chromatin
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reprogramming, and cell proliferation [159]. Therefore, TE mobility within lncRNA transcripts reflects
evolutionary and versatile functions in regulating cellular homeostasis.
The PIWI-piRNA axis has also been implicated in the silencing of transposable elements and
contributes to the development of human cancers [160]. Transcribed mostly from a cluster, piRNAs
are small non-coding RNAs that interact with PIWI proteins that are abundantly found in germ
cells [161]. PIWI proteins interact with DNA methylation and chomatin modifications to silence TEs
while maintaining the ability of germ stem cells for self-renewing [162]. In addition, the piRNA
pathway interacts with the p53 protein to restrict mobile element insertions and regulate chromatin
repressive marks in the 5′ of LINE1 sequences [62]. One of the most important roles of the piRNA-PIWI
protein complex is to protect germ cells from transposon insertions [160,163]. In cells that are previously
exposed to TEs, piRNAs containing a complementary TE sequence will induce degradation through
Piwi proteins [164]. In the first encounter to TEs, piRNA transcripts that are complementary to the
TE RNA can induce degradation through the piRNA-Piwi complex [165]. The piRNA-Piwi axis
has also been associated with the maintenance of genomic imprinting through DNA methylation in
the Rasgfr locus, in which the differentially methylated region contains the LINE1 sequence [166].
Correspondingly, the deregulation of PIWI proteins and transposable elements has been reported in
gliomas, sarcomas, and adenocarcinomas [160].
7. Conclusions
The above compiled results and observations suggest an important role of TEs in transcriptional
control, genomic instability, chromosomal rearrangements, non-coding RNA regulation, and oncogenic
activation. Although a direct association between TE insertion and cancer initiation still has to be
clarified, the deregulation of TEs is closely linked to cancers of various etiologies. Bioinformatic screens
have revealed mutagenenic TE insertions in different types of cancers. TE insertions also function as a
reservoir of endogenous gene regulatory factors that have been co-opted by the human genome to
control gene expression, as well as cellular phenotypes. After co-option or exaptation, insertions of
TEs can provide novel transcription factor binding sites in the promoters, enhancers, or insulators,
leading to cancer specific activation. TEs flanking ncRNA genes are also involved in ncRNA biogenesis.
In addition, repetitive sequences within TEs are important loci for the complementary binding of
ncRNAs acting as a reservoir for ncRNA inactivation. Therefore, the deregulation of TEs affects
genomic stability, transcription, and non-coding RNA regulation, leading to cancer development and
progression (please see Figure 3). However, the mechanisms for TE-mediated oncogenic activation
need to be further investigated to reveal new insights into carcinogenesis and identify novel targets
for therapeutic interventions. Clarification of the specific epigenetic regulation of TEs in such studies
may raise the possibility of applying epigenetic agents in TE-driven cancers such as demethylase
and bromodomain inhibitors; that are now in preclinical and clinical trials for solid tumors and
hematological malignancies.
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